Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Isabella M, Mayer"'
Autor:
Belinda S, Schmalzbauer, Teresemary, Thondanpallil, Gerwin, Heller, Alessia, Schirripa, Clio-Melina, Sperl, Isabella M, Mayer, Vanessa M, Knab, Sofie, Nebenfuehr, Markus, Zojer, André C, Mueller, Frédéric, Fontaine, Thorsten, Klampfl, Veronika, Sexl, Karoline, Kollmann
Publikováno v:
Cancers. 14(6)
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ebecb1483b53b7f57229c41bd0f3eb22
https://pubmed.ncbi.nlm.nih.gov/35326705
https://pubmed.ncbi.nlm.nih.gov/35326705
Autor:
Belinda S. Schmalzbauer, Teresemary Thondanpallil, Gerwin Heller, Alessia Schirripa, Clio-Melina Sperl, Isabella M. Mayer, Vanessa M. Knab, Sofie Nebenfuehr, Markus Zojer, André C. Mueller, Frédéric Fontaine, Thorsten Klampfl, Veronika Sexl, Karoline Kollmann
Publikováno v:
Cancers; Volume 14; Issue 6; Pages: 1554
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3d8e2b2f98b0839d01ed86ea56bd8a
https://doi.org/10.3390/cancers14061554
https://doi.org/10.3390/cancers14061554